Clinical Trial Update: CISH Inactivated TILs in the Treatment of NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating CISH-inactivated tumor-infiltrating lymphocytes for non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISH-inactivated TILs

Snippet

Sponsor: Intima Bioscience, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: WITHDRAWN